戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 otentially actionable factors, contribute to medication nonadherence.
2 ently associated with a higher likelihood of medication nonadherence.
3 e provider, but many reported antiretroviral medication nonadherence.
4 d the association between life chaos and CVD-medication nonadherence.
5 to measure life chaos is associated with CVD-medication nonadherence.
6 07; 95% CI [1.02-1.12]) in odds of reporting medication nonadherence.
7 ied as a potential objective tool to monitor medication nonadherence.
8 or relatively brief periods of antipsychotic medication nonadherence.
9 aire, was associated with increased risk for medication nonadherence.
10 layed care because of cost, and cost-related medication nonadherence.
11 verse events, patient-reported symptoms, and medication nonadherence.
12 for consumer goods may increase cost-related medication nonadherence.
13 on viral response, safety, tolerability, and medication nonadherence.
14 f measuring adherence, (2) the prevalence of medication nonadherence, (3) the association between non
15                                              Medication nonadherence, a major problem in cardiovascul
16 ls had 8.4-times higher odds of cost-related medication nonadherence (adjusted OR [aOR], 8.39 [95% CI
17                                              Medication nonadherence after solid organ transplantatio
18 uggests that these costs are associated with medication nonadherence and considerable economic burden
19 d clinically significant association between medication nonadherence and glaucomatous vision loss.
20 d to determine the association between prior medication nonadherence and HT nonadherence.
21 access, including self-reported cost-related medication nonadherence and inability to see a physician
22 re is currently no reliable method to detect medication nonadherence and prevent allograft rejection.
23 injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spe
24 arker, compared with SD alone, for assessing medication nonadherence and the possibility of allograft
25                             Antihypertensive medication nonadherence and the white coat effect, defin
26 , if any, of these low-cost interventions on medication nonadherence and to identify their most usefu
27 inant causes of readmissions were changes in medication/nonadherence and supraventricular arrhythmia.
28 drug costs contribute to financial toxicity, medication nonadherence, and adverse cardiovascular (CV)
29 existing psychiatric research: misdiagnosis, medication nonadherence, and treatment efficacy and expr
30 aOR, 1.27 [95% CI, 1.16-1.40]), cost-related medication nonadherence (aOR, 1.43 [95% CI, 1.30-1.57]),
31 1) automated identification of patients with medication nonadherence at the time of the visit; (2) pr
32 wing were associated with higher life chaos: medication nonadherence (beta=1.86; 95% confidence inter
33       The 2 ethnic groups were comparable on medication nonadherence, but whites tended to have poore
34                                              Medication nonadherence contributed to unfavorable treat
35                                 Cost-related medication nonadherence; cost coping strategies; desire
36                                 Cost-related medication nonadherence (CRN) has been a persistent prob
37 e prevalence and persistence of cost-related medication nonadherence (CRN) in a population with high-
38 ssion affects the prevalence of cost-related medication nonadherence (CRN) in elderly patients and pa
39 tification of patients with antihypertensive medication nonadherence did not lead to improvements in
40 sadvantaged areas may be at greater risk for medication nonadherence due to barriers such as lower ac
41                    The later consequences of medication nonadherence, especially early declines in ad
42                                              Medication nonadherence has been increasingly recognized
43 ldhood sexual abuse (hazard ratio=1.85), and medication nonadherence (hazard ratio=1.39) were associa
44                                              Medication nonadherence history may play an important ro
45 g social isolation, medical care insecurity, medication nonadherence, housing instability, and lack o
46                                              Medication nonadherence imposes high morbidity, mortalit
47           They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs.
48 cations, and the recognized complications of medication nonadherence in adults with epilepsy, identif
49                Depression is associated with medication nonadherence in patients with ACS, but it is
50                      Nearly 43% reported CVD-medication nonadherence in the past month.
51 bility as a self-report instrument to assess medication nonadherence in transplantation.
52                                 Cost-related medication nonadherence included taking smaller doses or
53                                              Medication nonadherence is a growing concern to clinicia
54                                              Medication nonadherence is a leading cause of graft loss
55              Acute rejection associated with medication nonadherence is a major cause of allograft lo
56                                     Although medication nonadherence is a major cause of rejection, t
57                              Early declining medication nonadherence is associated with adverse clini
58                                              Medication nonadherence is associated with worse outcome
59                                              Medication nonadherence is common among patients with he
60                                              Medication nonadherence is common and is associated with
61                                              Medication nonadherence is common and results in prevent
62                                              Medication nonadherence is present in nearly half of pat
63                                              Medication nonadherence (MNA) after solid organ transpla
64                                              Medication nonadherence (MNA) is considered to be the pr
65 " is to become a reality, then solutions for medication nonadherence must be found and implemented.
66                         We aimed to identify medication nonadherence (noninitiation, nonimplementatio
67            This study examined the effect of medication nonadherence on the return of positive sympto
68 patients were excluded, primarily because of medication nonadherence or change in diagnosis.
69                    This may have been due to medication nonadherence or, alternatively, due to the we
70  CI, 1.41-2.14; P < .001), have cost-related medication nonadherence (OR, 1.42; 95% CI, 1.11-1.82; P
71 inancial toxicity measures (eg, cost-related medication nonadherence, personal and/or health care-rel
72                      To improve cost-related medication nonadherence, prescribers and clinical staff
73 ence of both uncontrolled blood pressure and medication nonadherence promote interest in developing d
74 and food insecurity is one of the modifiable medication nonadherence risk factors.
75                             As hypothesized, medication nonadherence robustly predicted a return of p
76  abandonment represents a small component of medication nonadherence, the correlates to abandonment h
77 amine the link from cognitive impairment and medication nonadherence to clinical outcomes (eg, hospit
78                                    In HFrEF, medication nonadherence was associated with worse health
79                                              Medication nonadherence was obtained through linkage of
80                                 Cost-related medication nonadherence was reported by 20.2% of partici
81                                              Medication nonadherence was reported by patients in 8.0%
82                                              Medication nonadherence was the reason for 58% (21 of 36
83                Patient-reported symptoms and medication nonadherence were similar.
84 edication costs, and history of cost-related medication nonadherence) were obtained immediately befor
85                                              Medication nonadherence, which has been estimated to aff
86       More than 1 in 4 participants reported medication nonadherence, which was associated with worse
87       Three sets of operational criteria for medication nonadherence with differing levels of severit
88 verse drug events with or without misuse and medication nonadherence with unfavorable clinical evolut